Table 1.
Baseline characteristics of cases and non-cases of major cardiovascular events (MCVE) during 4.9 year follow up (N = 9,251)*
| Major cardiovascular events | ||
|---|---|---|
| Cases (n=729) | Non-cases (n=8522) | |
| Treatment: Atorvastatin 80 mg, % | 45.1 | 50.4 |
| Age, years | 62.2 (8.9) | 60.9 (8.8) |
| Height, cm | 173 (9) | 172 (9) |
| Weight, kg | 87.2 (16.9) | 84.5 (15.3) |
| BMI, kg/m2 | 29.3 (5.0) | 28.5 (4.5) |
| Blood pressure, mmHg | ||
| Systolic | 132.9 (17.7) | 130.4 (16.6) |
| Diastolic | 78.3 (9.9) | 77.9 (9.4) |
| Men, % | 83.4 | 80.9 |
| White, % | 93.3 | 94.4 |
| Cardiovascular history, % | ||
| Smoking | ||
| Current | 18.1 | 12.5 |
| Previous | 61.3 | 63.7 |
| Never | 20.6 | 23.8 |
| Diabetes | 23.2 | 14.0 |
| Hypertension | 66.3 | 52.7 |
| Myocardial infarction | 67.9 | 57.2 |
| Angina | 85.5 | 81.1 |
| Cerebrovascular disease | 11.1 | 4.5 |
| Peripheral vascular disease | 20.4 | 10.9 |
| Congestive heart failure | 15.5 | 6.9 |
| Arrhythmia | 23.7 | 17.8 |
| Coronary revascularization | ||
| Angioplasty | 52.3 | 54.2 |
| Bypass | 55.3 | 45.8 |
| Metabolic syndrome, % | 64.3 | 54.8 |
| Chronic kidney disease, % | 38.9 | 31.5 |
| Baseline lipids and apolipoproteins, mg/dL: Mean (SD) | ||
| Total cholesterol | 176.9 (24.6) | 174.3 (23.6) |
| LDL cholesterol | 100.2 (17.5) | 97.1 (17.4) |
| HDL cholesterol | 45.4 (10.1) | 47.6 (11.0) |
| Triglycerides | 158.0 (77.4) | 148.9 (69.0) |
| Median [25th, 75th percentiles] | 138.5 [103.5,194.3] | 133.5 [101.0,181.0] |
| Apolipoprotein A-I | 142.9 (23.1) | 146.5 (24.9) |
| Apolipoprotein B | 115.1 (20.2) | 110.5 (19.0) |
| Year 1 lipids and apolipoproteins, mg/dL: Mean (SD) | ||
| Total cholesterol | 166.8 (34.6) | 162.2 (32.3) |
| LDL cholesterol | 91.8 (27.1) | 87.7 (25.5) |
| HDL cholesterol | 44.6 (10.5) | 46.3 (11.1) |
| Triglycerides | 153.3 (82.2) | 142.2 (81.8) |
| Median [25th, 75th percentiles] | 132.0 [95.0, 192.0] | 123.0 [90.0, 171.0] |
| Apolipoprotein A-I | 140.7 (24.7) | 144.4 (24.8) |
| Apolipoprotein B | 106.5 (25.6) | 101.7 (23.9) |
| Concomitant medication, % | ||
| ACE inhibitor | 36.4 | 26.4 |
| Angiotensin II receptor blockers | 6.6 | 5.0 |
| Beta blockers | 55.6 | 53.8 |
| Calcium channel blockers | 34.3 | 26.0 |
| Aspirin | 80.5 | 87.3 |
| Coumadin or other antiplatlets | 4.5 | 2.9 |
| Prior use of statins | 60.6 | 62.7 |
| Other laboratory parameters: Mean (SD) | ||
| White blood cells (103/mm3) | 6.57 (1.64) | 6.27 (1.62) |
| Glucose (mg/dL) | 113.4 (36.7) | 106.9 (29.4) |
| Uric acid (mmol/L) | 6.43 (1.50) | 6.17 (1.38) |
| Blood urea nitrogen (mg/dL) | 17.77 (5.74) | 16.79 (4.77) |
| Lactate dehydrogenase (mg/dL) | 83.5 (17.5) | 81.6 (17.3) |
*
The analysis includes only subjects who survived to the year 1 visit without a MCVE and with complete year 1 lipids data since year 1 lipids data were included in the analysis model as predictor variables in all of the subsequent analyses. SD= standard deviation.